tirzepatide diabetes prevention A 3-year study of in participants with obesity and prediabetes showed substantial and sustained weight reduction and decreased risk of progression to with tirzepatide, as compared with placebo. Full SURMOUNT-1 Effect of Tirzepatide on Body

The double-blind, randomised, placebo-controlled Phase 2 trial evaluated the efficacy and safety of HRS9531 in obese adults without diabetes

Conclusion Compounded GLP-1 therapies are likely to remain part of clinical practice as long as shortages, affordability challenges, and growing patient demand continue

[21] [22] Some more serious side effects include: [12] Ongoing pain that begins in the upper left or middle of the stomach but may spread to the back Vomiting Hives, rash, itching Difficulty breathing or swallowing Swelling of lips, tongue, face, or throat Vision changes Fast heartbeat Dizziness or fainting Pain in the upper stomach, fever, yellowing of skin or eyes, or clay-colored stools Other reported adverse effects of dulaglutide include a small mean increase in heart rate, small decrease in systolic blood pressure and increases in pancreatic enzymes

A doctor can assess your medical history, current health conditions, and weight loss goals to determine if this combination is appropriate for you

Tirzepatide is a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors

Mean change in body weight from baseline at week 40 was 69 kg with semaglutide 20 mg and 60 kg with semaglutide 10 mg and 64 kg with semaglutide 20 mg and 56 kg with semaglutide 10 mg